Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell Disease

Recruiting Observational Study
Sickle Cell Disease
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
2 – 99
Sex
Any
Study type
Observational
Participants needed
50 (estimated)
Sponsor
National Human Genome Research Institute (NHGRI) · NIH
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The purpose of this research study is to look at genes and determine how they interact with each other to find changes that could explain why some people's immune systems may respond to blood transfusions. This response is called an alloimmune response. We strongly believe that when someone has an alloimmune response, it is caused by changes in their genes. We plan to compare changes in the genes …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
* INCLUSION CRITERIA To be eligible to participate in this study, an individual must meet all of the following criteria: 1\. Individual (\> 2 years of age) with confirmed SCD diagnosis who meets at least one of the following conditions: 1. History of greater than ten administered transfusions or …
Contacts

Emilyn C Banfield

(240) 328-0965

SCDtransfusionstudy@mail.nih.gov

CONTACT

Neil A Hanchard, M.D.

(301) 594-2151

neil.hanchard@nih.gov

CONTACT